Hikma Pharmaceuticals PLC (HIK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hikma Pharmaceuticals PLC (HIK) has a cash flow conversion efficiency ratio of 0.063x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX161.00 Million ≈ $19.59K USD) by net assets (GBX2.55 Billion ≈ $310.38K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Hikma Pharmaceuticals PLC balance sheet quality to measure how much of total assets are equity-financed.
Hikma Pharmaceuticals PLC - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Hikma Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Hikma Pharmaceuticals PLC to evaluate the quality of earnings relative to operating cash generation.
Hikma Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hikma Pharmaceuticals PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Multi Retail Group Ltd
TA:MRG
|
0.584x |
|
NextNRG Inc.
NASDAQ:NXXT
|
0.097x |
|
Dye & Durham Ltd
TO:DND
|
0.002x |
|
Inch Kenneth Kajang Rubber PLC
KLSE:2607
|
-0.003x |
|
Mineralbrunnen Überkingen-Teinach GmbH & Co. KGaA
F:MUT3
|
0.033x |
|
COLUMBUS ENERGY S.A. ZY 7
F:0Q8
|
0.387x |
|
UBIVELOX Inc
KQ:089850
|
-0.048x |
|
Stalprofil S.A.
WAR:STF
|
0.114x |
Annual Cash Flow Conversion Efficiency for Hikma Pharmaceuticals PLC (2002–2024)
The table below shows the annual cash flow conversion efficiency of Hikma Pharmaceuticals PLC from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see Hikma Pharmaceuticals PLC stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX2.32 Billion ≈ $282.40K |
GBX564.00 Million ≈ $68.62K |
0.243x | -11.71% |
| 2023-12-31 | GBX2.21 Billion ≈ $268.77K |
GBX608.00 Million ≈ $73.98K |
0.275x | +11.55% |
| 2022-12-31 | GBX2.15 Billion ≈ $261.35K |
GBX530.00 Million ≈ $64.49K |
0.247x | -4.59% |
| 2021-12-31 | GBX2.47 Billion ≈ $300.16K |
GBX638.00 Million ≈ $77.63K |
0.259x | +19.72% |
| 2020-12-31 | GBX2.15 Billion ≈ $261.35K |
GBX464.00 Million ≈ $56.46K |
0.216x | -2.56% |
| 2019-12-31 | GBX2.13 Billion ≈ $259.04K |
GBX472.00 Million ≈ $57.43K |
0.222x | -12.51% |
| 2018-12-31 | GBX1.70 Billion ≈ $206.48K |
GBX430.00 Million ≈ $52.32K |
0.253x | -12.60% |
| 2017-12-31 | GBX1.53 Billion ≈ $185.91K |
GBX443.00 Million ≈ $53.90K |
0.290x | +138.57% |
| 2016-12-31 | GBX2.41 Billion ≈ $293.35K |
GBX293.00 Million ≈ $35.65K |
0.122x | -55.11% |
| 2015-12-31 | GBX1.35 Billion ≈ $164.50K |
GBX366.00 Million ≈ $44.53K |
0.271x | -22.55% |
| 2014-12-31 | GBX1.22 Billion ≈ $147.95K |
GBX425.00 Million ≈ $51.71K |
0.350x | +7.24% |
| 2013-12-31 | GBX1.03 Billion ≈ $125.81K |
GBX337.00 Million ≈ $41.00K |
0.326x | +51.70% |
| 2012-12-31 | GBX847.85 Million ≈ $103.16K |
GBX182.16 Million ≈ $22.16K |
0.215x | +67.18% |
| 2011-12-31 | GBX798.63 Million ≈ $97.17K |
GBX102.64 Million ≈ $12.49K |
0.129x | -30.52% |
| 2010-12-31 | GBX750.30 Million ≈ $91.29K |
GBX138.79 Million ≈ $16.89K |
0.185x | +19.78% |
| 2009-12-31 | GBX683.26 Million ≈ $83.13K |
GBX105.52 Million ≈ $12.84K |
0.154x | +62.51% |
| 2008-12-31 | GBX609.00 Million ≈ $74.10K |
GBX57.87 Million ≈ $7.04K |
0.095x | -6.41% |
| 2007-12-31 | GBX424.66 Million ≈ $51.67K |
GBX43.12 Million ≈ $5.25K |
0.102x | +18.42% |
| 2006-12-31 | GBX349.80 Million ≈ $42.56K |
GBX29.99 Million ≈ $3.65K |
0.086x | -24.65% |
| 2005-12-31 | GBX287.48 Million ≈ $34.98K |
GBX32.71 Million ≈ $3.98K |
0.114x | -49.70% |
| 2004-12-31 | GBX145.18 Million ≈ $17.66K |
GBX32.84 Million ≈ $4.00K |
0.226x | -25.43% |
| 2003-12-31 | GBX60.47 Million ≈ $7.36K |
GBX18.35 Million ≈ $2.23K |
0.303x | +1.52% |
| 2002-12-31 | GBX48.03 Million ≈ $5.84K |
GBX14.35 Million ≈ $1.75K |
0.299x | -- |
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and spe… Read more